Fig. 1

Generation of genetic-modified MSCs secreting neutralizing SARS-CoV-2 mAbs. (a) Schematic representation of engineered MSCs expressing neutralizing SARS-CoV-2 2–15, XGv347, and LY-CoV1404 mAbs. (b) Normalized binding to S1 and RBD of SARS-CoV-2 for mAbs secreted by MSCs clones (triangles: green, S1-binding; gray, not S1-binding; inverted triangles: green, RBD-binding; gray, not RBD-binding, the cutoff line for positive: OD ratio > 0.2). OD, optical density in ELISA; WT: untransfected MSCs; C1: vector control; C2: wt control. See also Figure S1. (c) Quantification of the released mAbs levels by antigen (S1)-specific ELISA using the supernatants collected after 96 h of culture from the top 18 neutralizing MSCs clones (mean ± SD).